Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Rating of “Moderate Buy” by Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $182.47.

Several analysts have issued reports on JAZZ shares. Barclays reissued an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday. Royal Bank of Canada decreased their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday.

Jazz Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ JAZZ opened at $143.53 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market cap of $8.68 billion, a P/E ratio of 20.22, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $148.06. The firm has a 50-day simple moving average of $126.28 and a two-hundred day simple moving average of $118.79.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. The trade was a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 5,053 shares of company stock valued at $617,442. 4.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mackenzie Financial Corp grew its holdings in Jazz Pharmaceuticals by 493.3% in the fourth quarter. Mackenzie Financial Corp now owns 20,286 shares of the specialty pharmaceutical company’s stock worth $2,498,000 after purchasing an additional 16,867 shares during the last quarter. Forum Financial Management LP purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth $245,000. GF Fund Management CO. LTD. purchased a new position in Jazz Pharmaceuticals in the fourth quarter worth $156,000. MidWestOne Financial Group Inc. grew its holdings in shares of Jazz Pharmaceuticals by 10.4% during the fourth quarter. MidWestOne Financial Group Inc. now owns 24,347 shares of the specialty pharmaceutical company’s stock valued at $2,998,000 after buying an additional 2,284 shares during the last quarter. Finally, Elequin Capital LP grew its holdings in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 183 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.